Background The increasing antimalarial drug resistance is a significant hindrance to malaria control and elimination programs. For the last six decades, chloroquine (CQ) plus pyrimethamine remains the first-line treatment for P. vivax malaria.
Hargobinder Kaur +7 more
doaj +1 more source
High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. [PDF]
BACKGROUND: Sulphadoxine-pyrimethamine (SP) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants
Gesase Samwel +54 more
core +2 more sources
The emergence and transmission of resistance to antimalarial treatments continue to hamper malaria elimination efforts. A scoping review was undertaken regarding the impact of antimalarial treatment in the human population on the emergence and ...
Aleisha R. Brock +3 more
doaj +1 more source
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children. [PDF]
BACKGROUND: Use of different methods for assessing the efficacy of artemisinin-based combination antimalarial treatments (ACTs) will result in different estimates being reported, with implications for changes in treatment policy.
Pinoges Loretxu +55 more
core +1 more source
Quality of antimalarial drugs and antibiotics in Papua New Guinea : a survey of the health facility supply chain [PDF]
Poor-quality life-saving medicines are a major public health threat, particularly in settings with a weak regulatory environment. Insufficient amounts of active pharmaceutical ingredients (API) endanger patient safety and may contribute to the ...
Betuela Inoni +40 more
core +2 more sources
Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery
Melkamu Adigo Shibeshi, Zemene Demelash Kifle, Seyfe Asrade Atnafie Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Zemene Demelash KifleDepartment of ...
Shibeshi MA, Kifle ZD, Atnafie SA
doaj
Drug resistant falciparum malaria and the use of artesunate-based combinations : focus on clinical trials sponsored by TDR [PDF]
Antimalarial drug resistance has now become a serious global challenge and is the principal reasonfor the decline in antimalarial drug efficacy. Malaria endemic countries need inexpensive and efficaciousdrugs.
Walter R.J. Taylor, Jean Rigal & Piero L. Olliaro
doaj
A database of antimalarial drug resistance
A large investment is required to develop, license and deploy a new antimalarial drug. Too often, that investment has been rapidly devalued by the selection of parasite populations resistant to the drug action.
Ringwald Pascal, Sibley Carol
doaj +1 more source
Malaria is still one of the major killer parasitic diseases in tropical settings, posing a public health threat. The development of antimalarial drug resistance is reversing the gains made in attempts to control the disease.
Melissa Louise Stofberg +3 more
doaj +1 more source
Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. [PDF]
BACKGROUND\ud \ud Intermittent preventive treatment (IPT) is a promising intervention for malaria control, although there are concerns about its impact on drug resistance.\ud \ud METHODS\ud \ud The key model inputs are age-specific values for a) baseline
Sutherland Colin +18 more
core +1 more source

